Understanding the Key Considerations to Achieve Large Scale & Commercial Manufacture

Time: 12:30 pm


  • Cellectis’ integrative approach with an industrial manufacturing platform and established end-to-end supply chain
    – US based large-scale production plant with state-of-the-art technology to manufacture products for clinical development and future commercial use
    – European based production plant of starting materials (plasmids, RNAs, and vectors)
  • Strategic and technical considerations when manufacturing allogeneic CAR-T therapies: process and analytical development strategies, scaling-up and technology transfers